权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

The Intermountain West-Atlantic Center (InterACT) for the APS Phenotyping Consortium

APS 表型联盟的山间西大西洋中心 (InterACT)

基本信息

批准号：
10649343
负责人：
Christina Eleanor Barkauskas
金额：
$ 19.31万
依托单位：
IHC HEALTH SERVICES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-05-01 至 2029-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10649343
关键词：
Accounting Acute Acute Respiratory Distress Syndrome Address Biological Biological Markers Biology COVID-19/ARDS Clinical Clinical Data Clinical Trials Computers Critical Illness Data Data Analyses Data Collection Disease Enrollment Future Goals Heterogeneity Hyaluronan Inflammation Inflammatory Intensive Care Units International Investigation Lead Machine Learning Measures Mechanical ventilation Methodology Methods Molecular Noise Outcome Output Pathologic Pathway interactions Patient-Focused Outcomes Patients Pattern Pharmacotherapy Phenotype Play Pneumonia Population Process Receptor Activation Records Recovery Role Scientist Sepsis Signal Transduction Site Statistical Methods Subgroup Supportive care Syndrome Target Populations Techniques Therapeutic Therapeutic Trials Toll-like receptors Validation Variant Work clinical application clinical care cohort common treatment cytokine design disease phenotype experience immune activation immunoregulation improved improved outcome injury and repair innovation machine learning method molecular marker mortality novel participant enrollment patient response prospective receptor for advanced glycation endproducts sepsis induced ARDS social culture social determinants statistical and machine learning stem cells targeted treatment tissue injury tissue repair

项目摘要

Project Summary This proposal presents the Intermountain West-Atlantic Center (InterACT), which brings together four robust investigative sites to participate in the APS Phenotypes Consortium. InterACT proposes to use robust statistical and machine learning methods to phenotype patients with Acute Respiratory Distress Syndrome (ARDS), pneumonia, and sepsis in two broad proposals. In the first proposal for the entire Consortium, we will use multiplex cytokine arrays and clinical variables in the setting of normalized treatment trajectories to improve the accuracy of phenotyping by accounting for the role treatment plays. This method creates phenotypes that will be confirmed, with an eye toward therapeutic implications, in emulated clinical trials. In the second proposal for the Center specifically, we will focus our statistical methodology on new work investigating the pattern of tissue injury and repair, with a focus on hyaluronan and soluble Receptor for Advanced Glycation Endproducts (sRAGE) as tissue injury biomarkers and predictors of dysregulated inflammation. This work will culminate in emulated trials of novel agents that modulate the pathologic consequences of tissue injury. Together these highly innovative proposals promise actionable, treatment-responsive patient phenotypes for future clinical trials.

项目总结